Prognostic value of lncRNA ROR expression in various cancers: a meta-analysis

Background: There is a dispute on the prognostic value of long non-coding RNA regulator of reprogramming (lncRNA ROR) in cancers. The purpose of the present study was to evaluate the prognostic significance of lncRNA ROR expression in human cancers. Methods: PubMed, Embase, and Cochrane Library were searched to look for relevant studies. The meta-analyses of prognostic and clinicopathological parameters (CPs) were conducted. Results: A total of ten studies were finally included into the meta-analysis. High lncRNA ROR expression was significantly associated with shorter overall survival (hazard ratio [HR] = 2.88, 95% confidence interval [CI] = 2.16–3.84, P<0.01) and disease-free survival (HR = 3.25, 95% CI = 2.30–4.60, P<0.01) compared with low lncRNA ROR expression. Besides, high lncRNA ROR expression was obviously related to more advanced clinical stage (P<0.01), earlier tumor metastasis (P=0.02), lymph node metastasis (P<0.01), and vascular invasion (P<0.01) compared with low lncRNA ROR expression. However, there was no significant correlation between lncRNA ROR expression and other CPs, including age (P=0.18), gender (P=0.33), tumor size (P=0.25), or tumor differentiation (P=0.13). Conclusion: High lncRNA ROR expression was associated with worse prognosis in cancers. LncRNA ROR expression could serve as an unfavorable prognostic factor in various cancers.

Download Full-text

Prognostic significance of long non-coding RNA DANCR expression in human cancers: A systematic review and meta-analysis

Bioscience Reports ◽

10.1042/bsr20181627 ◽

2019 ◽

Cited By ~ 1

Author(s):

Wei Liu ◽

Qin-Peng Wang ◽

Jia Guo

Keyword(s):

Meta Analysis ◽

Clinical Stage ◽

Prognostic Significance ◽

Disease Free Survival ◽

Cancer Prognosis ◽

Advanced Clinical Stage ◽

Protein Coding ◽

Human Cancers ◽

Non Coding Rna ◽

Long Non Coding Rna

Background: Several studies demonstrated that long non-coding RNA differentiation antagonizing non-protein coding RNA (lncRNA DANCR) expression might have the potential capacity to predict the cancer prognosis, however, definite conclusion has not been obtained. The aim of this meta-analysis was to evaluate the prognostic value of lncRNA DANCR expression in cancers. Methods: PubMed, Web of Science, Scopus and Embase were comprehensively searched for relevant studies. Studies meeting all inclusion standards were included into this meta-analysis. The analysis of overall survival (OS), disease-free survival (DFS) or clinicopathological features was conducted. Results: Eleven studies containing 1,154 cancer patients were analyzed in this meta-analysis. The results showed, compared with low lncRNA DANCR expression, high lncRNA DANCR expression was significantly associated with shorter OS (HR=1.85, 95%CI=1.52-2.26, P<0.01) and DFS (HR=1.82, 95%=1.43-2.32, P<0.01) in cancers. Besides, high lncRNA DANCR expression predicted deeper tumor invasion (P<0.01), earlier lymph node metastasis (P<0.01), earlier distant metastasis (P<0.01) and more advanced clinical stage (P<0.01) compared with low lncRNA DANCR expression in cancer populations. Conclusion: High lncRNA DANCR expression was associated with worse prognosis compared with low lncRNA DANCR expression in cancers. LncRNA DANCR expression could serve as a prognostic factor of human cancers.

Download Full-text

Prognostic significance of LncRNA GHET1 expression in various cancers: a systematic review and meta-analysis

Bioscience Reports ◽

10.1042/bsr20190608 ◽

2019 ◽

Vol 39 (10) ◽

Cited By ~ 3

Author(s):

Jing Ye ◽

Haiyan Sun ◽

Zhengquan Feng ◽

Qiqin Zhang ◽

Yongliang Xia ◽

...

Keyword(s):

Meta Analysis ◽

Clinical Stage ◽

Prognostic Significance ◽

The Cancer Genome Atlas ◽

Cancer Prognosis ◽

Advanced Clinical Stage ◽

Human Cancers ◽

Non Coding Rna ◽

Cancer Genome Atlas ◽

Meta Analyses

Abstract Background: Dysregulated expression of long non-coding RNA gastric carcinoma high expressed transcript 1 (lncRNA GHET1) has been observed in several cancers, however, definite conclusion on the prognostic value of lncRNA GHET1 expression in human cancers has not been determined. The aim of this meta-analysis was to evaluate the prognostic significance of lncRNA GHET1 expression in cancers. Methods: PubMed, Web of Science and Embase were comprehensively searched for relevant studies. Meta-analyses of overall survival (OS) and clinicopathological features were conducted. Results: Ten studies were finally analyzed in the present study. High lncRNA GHET1 expression was associated with shorter OS than low lncRNA GHET1 expression in cancers (hazard ratio (HR) = 2.59, 95% CI = 1.93–3.47, P<0.01). Online cross-validation using The Cancer Genome Atlas (TCGA) data observed similar results (HR = 1.10, P<0.05). When compared with low lncRNA GHET1 expression, high lncRNA GHET1 expression was related to larger tumor size (P<0.01), worse differentiation (P<0.01), earlier distant metastasis (P=0.02), earlier lymph node metastasis (P<0.01) and more advanced clinical stage (P<0.01). Conclusion: High lncRNA GHET1 expression is associated with worse cancer prognosis and can serve as a promising prognostic factor of human cancers.

Download Full-text

Prognostic significance of microRNA-135 in patients with digestive system cancers: a systematic review and meta-analysis

Bioscience Reports ◽

10.1042/bsr20190845 ◽

2019 ◽

Vol 39 (12) ◽

Author(s):

Ce Chao ◽

Chen Sang ◽

Min Wang ◽

Zijin Wang ◽

Yanfei Li ◽

...

Keyword(s):

Prognostic Value ◽

Large Scale ◽

Digestive System ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

The Cancer Genome Atlas ◽

Cochrane Library ◽

Free Survival ◽

Non Coding Rna

Abstract Background: MicroRNA-135 (miR-135) is a well-known non-coding RNA that has been demonstrated to participate in tumorigenesis and cancer development; however, the clinical prognostic value of miR-135 in digestive system cancers remains controversial. This meta-analysis aims to explore the potential value of miR-135 as a prognostic marker for digestive system cancers. Methods: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible articles published before 31 August 2019. Stata 12.0 software was used to analyze the overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) rates to access the prognostic value of miR-135 in digestive system cancers. We then used The Cancer Genome Atlas (TCGA) datasets to validate the meta-analysis results. Results A total of 1470 patients from 17 studies were included in this meta-analysis. The pooled results showed that enhanced miR-135 expression was significantly associated with poor OR (hazard ratio (HR): 1.790; 95% confidence interval (95% CI): 1.577–2.031; P=0.000), DFS (HR: 1.482; 95% CI: 0.914–2.403; P=0.110), and RFS (HR: 3.994; 95% CI: 1.363–11.697; P=0.012) in digestive system cancers. A sensitivity analysis confirmed the reliability of our findings, and no significant publication bias was observed. Conclusion: MiR-135 can be used as a novel biomarker for patients with digestive system cancers. We look forward to future large-scale clinical studies that will investigate the prognostic value of miR-135.

Download Full-text

Clinicopathologic and prognostic implications of Golgi Phosphoprotein 3 in colorectal cancer: A meta-analysis

PLoS ONE ◽

10.1371/journal.pone.0260035 ◽

2021 ◽

Vol 16 (11) ◽

pp. e0260035

Author(s):

Tao Wang ◽

Jiandong Fei ◽

Shuangfa Nie

Keyword(s):

Colorectal Cancer ◽

Data Extraction ◽

Meta Analysis ◽

Clinical Stage ◽

Prognostic Significance ◽

Disease Free Survival ◽

Tumor Stage ◽

Clinicopathological Characteristics ◽

Cochrane Library ◽

Advanced Clinical Stage

Background Golgi Phosphoprotein 3 (GOLPH3) has been implicated in the development of colorectal cancer (CRC). Nevertheless, the clinicopathological and prognostic roles of GOLPH3 in CRC remain undefined. We thus did a meta-analysis to assess GOLPH3 association with the clinicopathological characteristics of patients and evaluate the prognostic significance of GOLPH3 in CRC. Methods An electronic search for relevant articles was conducted in the PubMed, Cochrane Library, Web of Science, Medline, Embase, CNKI, and WanFang databases. Two independent reviewers searched all the literature and finished the data extraction and quality assessment. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were used to assess estimates. Stata software (version12.0) was employed to analyze the data. Results A total of 8 published studies were eligible (N = 723 participants). Meta-analysis revealed that GOLPH3 was found to be highly expressed in tumor tissues compared to that of adjacent colorectal tissues (OR, 2.63), and overexpression of GOLPH3 had significant relationship with advanced clinical stage (OR, 3.42). GOLPH3 expression was not correlated with gender (OR, 0.89), age (OR, 0.95), positive lymphatic metastasis (OR, 1.27), tumor size (OR, 1.12), poor differentiation of tumor (OR, 0.56) or T stage (OR, 0.70). Moreover, GOLPH3 overexpression was not associated with worse overall survival (OS) (HR = 1.14, 95% CI: 0.42–1.86, P>0.05) and disease-free survival (DFS) (HR = 0.80, 95% CI:-0.26–1.86, P>0.05). Conclusions GOLPH3 overexpression is correlated with tumor stage, which is an adverse clinicopathological characteristic of CRC. But, GOLPH3 can not serve as a useful biomarker in evaluating the progression of CRC.

Download Full-text

Diagnostic and prognostic significance of dysregulated expression of circular RNAs in osteosarcoma

10.21203/rs.3.rs-19087/v1 ◽

2020 ◽

Author(s):

Chenghao Zhang ◽

Jieyu He ◽

Lin Qi ◽

Zhixi Duan ◽

Lu Wan ◽

...

Keyword(s):

Meta Analysis ◽

Prognostic Significance ◽

Area Under The Curve ◽

Disease Free Survival ◽

Diagnostic Odds Ratio ◽

Cochrane Library ◽

Clinicopathological Parameters ◽

Circular Rnas ◽

Diagnostic Significance ◽

Enneking Stage

Abstract Background Circular RNAs (circRNAs) have emerged as pivotal regulators in osteosarcoma tumorigenesis and progression, but their prognostic and diagnostic significance remain unclear. Herein, we aimed to perform an updated meta-analysis to explore the clinical, diagnostic and prognostic values of circRNAs in osteosarcoma. Methods Several databases, including PubMed, Web of Science, EMBASE, Scopus and Cochrane Library, were systematically searched up to Mar 10, 2020. Eligible studies regarding the relationship between circRNAs levels and clinicopathological, diagnostic and prognostic values in osteosarcoma patients were included in this study. Pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to measure clinical characteristics, while hazard ratios (HRs) with 95% CIs were adopted to assess overall survival (OS) and disease-free survival (DFS). Results Overall, 26 relevant studies involving 1,652 patients with osteosarcoma were enrolled, with eighteen studies on clinicopathological parameters, ten on diagnosis and eighteen on prognosis. For clinical parameters, overexpression of oncogenic circRNAs was intimately correlated with larger tumor size (P <0.00001), advanced Enneking stage (P <0.00001), poor differentiation (P =0.0001), and distant metastasis (DM) (P <0.00001). In contrast, the downregulated circRNAs showed negative correlation with Enneking stage (P=0.002) and DM (P<0.0001). For the diagnostic values, the summary area under the curve (AUC) of circRNA for the discriminative efficacy between osteosarcoma patients and non-cancer counterparts was estimated to be 0.86 (95% CI: 0.83-0.89), with a weighted sensitivity of 0.80 (95% CI: 0.74-0.84), specificity of 0.80 (95%: 0.75-0.84), and diagnostic odds ratio (DOR) of 15.48 (10.85-22.10), respectively. For the prognostic significance, oncogenic circRNAs had poor OS (HR=1.92, 95% CI: 1.68-2.19) and DFS (HR=2.65, 95% CI: 2.02-3.49), while elevated expression of tumor-suppressor circRNAs were closely related to longer OS (HR=0.44, 95% CI: 0.28-0.69). Conclusions Taken together, our study showed that aberrantly expressed circRNA signatures could serve as potential predictive indicators in diagnosis and prognosis in patients with osteosarcoma.

Download Full-text

Diagnostic and Prognostic Significance of Dysregulated Expression of Circular RNAs in Osteosarcoma

10.21203/rs.3.rs-34455/v1 ◽

2020 ◽

Author(s):

Chenghao Zhang ◽

Jieyu He ◽

Lin Qi ◽

Zhixi Duan ◽

Lu Wan ◽

...

Keyword(s):

Meta Analysis ◽

Prognostic Significance ◽

Area Under The Curve ◽

Disease Free Survival ◽

Diagnostic Odds Ratio ◽

Cochrane Library ◽

Clinicopathological Parameters ◽

Circular Rnas ◽

Diagnostic Significance ◽

Enneking Stage

Abstract Background CircRNAs have emerged as pivotal regulators in osteosarcoma tumorigenesis and progression, but their prognostic and diagnostic significance remain unclear. Herein, we aimed to perform an updated meta-analysis to explore the clinical, diagnostic and prognostic values of circRNAs in osteosarcoma. Methods Several databases, including PubMed, Web of Science, EMBASE, Scopus and Cochrane Library, were systematically searched up to April 10, 2020. Eligible studies regarding the relationship between circRNAs levels and clinicopathological, diagnostic and prognostic values in osteosarcoma patients were included in this study. Pooled odds ratios with corresponding 95% confidence intervals were used to measure clinical characteristics, while hazard ratios with 95% CIs were adopted to assess overall survival (OS) and disease-free survival (DFS). Results Overall, 26 relevant studies involving 1,652 patients with osteosarcoma were enrolled, with eighteen studies on clinicopathological parameters, ten on diagnosis and eighteen on prognosis. For clinical parameters, overexpression of oncogenic circRNAs was intimately correlated with larger tumor size (P < 0.00001), advanced Enneking stage (P < 0.00001), poor differentiation (P = 0.0001), and distant metastasis (DM) (P < 0.00001). In contrast, the downregulated circRNAs showed negative correlation with Enneking stage (P = 0.002) and DM (P < 0.0001). For the diagnostic values, the summary area under the curve of circRNA for the discriminative efficacy between osteosarcoma patients and non-cancer counterparts was estimated to be 0.86 (95% CI: 0.83–0.89), with a weighted sensitivity of 0.80 (95% CI: 0.74–0.84), specificity of 0.80 (95%: 0.75–0.84), and diagnostic odds ratio of 15.48 (10.85–22.10), respectively. For the prognostic significance, oncogenic circRNAs had poor OS (HR = 1.92, 95% CI: 1.68–2.19) and DFS (HR = 2.65, 95% CI: 2.02–3.49), while elevated expression of tumor-suppressor circRNAs were closely related to longer OS (HR = 0.44, 95% CI: 0.28–0.69). Conclusions Taken together, our study showed that aberrantly expressed circRNA signatures could serve as potential biomarkers in diagnosis and prognosis in patients with osteosarcoma.

Download Full-text

Clinicopathological and Prognostic Significance of Platelet-Lymphocyte Ratio (PLR) in Gastric Cancer: A Meta-Analysis

10.21203/rs.2.17511/v1 ◽

2019 ◽

Author(s):

Xunlei Zhang ◽

Wenjing Zhao ◽

Yang Yu ◽

Xue Qi ◽

Li Song ◽

...

Keyword(s):

Gastric Cancer ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Cochrane Library ◽

Clinicopathological Parameters ◽

Poor Overall Survival ◽

Lymphocyte Ratio ◽

Platelet Lymphocyte Ratio ◽

Inflammatory Parameters

Abstract Background: Systemic inflammatory parameters, such as the elevator PLR (platelet-lymphocyte ratio), have been found to be associated with the prognosis in gastric cancer (GC); however, the results remain controversial. So we aimed to evaluate the prognostic role of the PLR in gastric cancer by conducting this meta-analysis. Methods: We performed a systematic literature search in PubMed, Embase and the Cochrane Library. The hazard ratio (HR) /Odds Ratio (OR) and its 95% confidence (CI) of survival outcomes and clinicopathological parameters were calculated. Results: A total of 38 studies (39 cohorts) with 23,317 GC patients were included in the final meta-analysis. The pooled results showed that elevated PLR was significantly associated with poor overall survival (OS) (HR: 1.37, 95% CI: 1.25-1.51, p < 0.001; I2= 82.10%, Ph < 0.001) and disease-free survival (DFS) (HR 1.52, 95%CI 1.22–1.90, P< 0.001, I2= 88.6%, Ph< 0.001) of GC patients. Furthermore, patients with elevated PLR had a higher risk of lymph node metastasis (OR = 1.33, 95% CI: 1.03–1.70, p=0.027), serosal invasion (T3 +T4) (OR = 1.58, 95% CI: 1.09–1.31, p=0.017) and increased advanced stage (III+IV) (OR = 1.37, 95% CI: 1.00–1.89, p=0.050). Conclusions: This meta-analysis demonstrated that elevated PLR was a prognostic factor for poor OS and DFS, and associated with clinicopathological parameters in patients with GC.

Download Full-text

TP73-AS1 as a Predictor of Clinicopathological Parameters and Prognosis in Human Malignancies: A Meta and Bioinformatics Analysis

10.21203/rs.3.rs-1124245/v1 ◽

2021 ◽

Author(s):

Caizhi Chen ◽

Jingjing Wang ◽

Yeqian Feng ◽

Ye Liang ◽

Yan Huang ◽

...

Keyword(s):

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

The Cancer Genome Atlas ◽

Prognostic Indicators ◽

Cochrane Library ◽

Clinicopathological Parameters ◽

Oncogenic Signaling ◽

Poor Overall Survival ◽

The Cochrane Library

Abstract Background: LncRNA TP73-AS1 is dysregulated in various tumors but the correlation between its expression and clinicopathological parameters and/or prognoses in cancer patients is inconclusive. Here, we performed a meta-analysis to evaluate the prognostic value of lncRNA TP73-AS1 for malignancies.Methods: We systematically searched four online databases including PubMed, the Web of Science, Embase, and the Cochrane Library for eligible articles published up to June 29/2020. Odds ratios (ORs) and Pooled hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the association of TP73-AS1 expression with prognostic and clinicopathological parameters. We further validated TP73-AS1 expression in various malignancies and its potential prognostic value using the GEPIA online database. We predicted potential biological processes and relevant signal mechanisms through the public databases.Results: A total of 26 studies including 1770 patients were analyzed to evaluate the relationship between TP73-AS1 expression, clinicopathological features and prognostic indicators. The results indicated that TP73-AS1 expression markedly correlates with TNM stage, tumor size, lymph node metastasis and distant metastasis. No correlation with age, gender or differentiation was observed. TP73-AS1 overexpression was a biomarker of poor Overall survival (OS) and Disease-Free-Survival (DFS). Dysregulated TP73-AS1 expression and its prognostic value in various cancers was validated based on The Cancer Genome Atlas (TCGA). Further biological function predictions indicated that TP73-AS1 was involved in pro-oncogenic signaling.Conclusions: The upregulation of LncRNA TP73-AS1 was related to detrimental clinicopathological parameters and can be considered an indicator of poor prognosis for cancer malignancies.

Download Full-text

Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers

10.21203/rs.3.rs-18849/v1 ◽

2020 ◽

Author(s):

Chenghao Zhang ◽

Chao Tu ◽

Xiaolei Ren ◽

Wenchao Zhang ◽

Lile He ◽

...

Keyword(s):

Overall Survival ◽

Meta Analysis ◽

Clinical Stage ◽

The Cancer Genome Atlas ◽

Clinicopathological Parameters ◽

Tumor Type ◽

Advanced Clinical Stage ◽

Non Coding Rna ◽

Tcga Dataset ◽

Stratified Analysis

Abstract Background: Recently, dysregulation of lncRNA SNHG12 has been determined in kinds of cancers. However, definite prognostic value of SNHG12 remains unclear. We conducted this meta-analysis to evaluate the association between SNHG12 expression levels and caner prognosis.Methods: A literature retrieval was conducted by searching kinds of databases. The meta-analysis of prognostic and clinicopathological parameters was performed by using Revman 5.2 and Stata 12.0 software. Besides, The Cancer Genome Atlas dataset was analyzed to validate the results in our meta-analysis via using Gene Expression Profiling Interactive Analysis.Results: High SNHG12 expression significantly predicted worse overall survival (HR=1.97, 95%CI 1.56-2.48, P<0.01) and recurrence-free survival (HR=1.71, 95%CI 1.05-2.78, P<0.01). Tumor type, sample size, survival analysis method, and cut-off value did not alter SNHG12 prognosis value according to stratified analysis results. Additionally, patients with elevated SNHG12 expression were more prone to unfavorable clinicopathological outcomes, including larger tumor size, lymph node metastasis, distant metastasis, advanced clinical stage. Online cross-validation in TCGA dataset further proved that cancer patients with upregulated SNHG12 expression had worse overall survival and disease-free survival.Conclusion: Elevated SNHG12 expression was associated with poor survival and unfavorable clinicopathological features in various cancers, and therefore might be a potential prognostic biomarker in human cancers.

Download Full-text

Prognostic Value of S100P Expression in Patients With Digestive System Cancers: A Meta-Analysis

Frontiers in Oncology ◽

10.3389/fonc.2021.593728 ◽

2021 ◽

Vol 11 ◽

Author(s):

Bi-Xia Liu ◽

Chao-Tao Tang ◽

Xi-Jian Dai ◽

Ling Zeng ◽

Fei Cheng ◽

...

Keyword(s):

Gastrointestinal Tract ◽

Prognostic Value ◽

Digestive System ◽

Meta Analysis ◽

Clinical Stage ◽

Cochrane Library ◽

High Morbidity ◽

Tumor Type ◽

Advanced Clinical Stage ◽

Anatomic Structure

BackgroundDigestive system cancers (DSCs) are associated with high morbidity and mortality. S100P has been reported as a prognostic biomarker in DSCs, but its prognostic value remains controversial. Accordingly, we conducted a meta-analysis to investigate whether S100P is correlated with overall survival (OS) of patients with DSCs. The relationship between S100P and clinicopathological features was also evaluated.MethodsWe systematically searched PubMed, Embase, Web of Science and Cochrane Library for eligible studies up to January 2020. In total, 16 publications with 1,925 patients were included.ResultsS100P overexpression was associated with poor OS of patient with DSCs (HR=1.54, 95% CI: 1.14–2.08, P=0.005). When stratified by anatomic structure, S100P overexpression was associated with poor prognosis in non-gastrointestinal tract cancers (HR=1.98, 95% CI: 1.44–2.72, P<0.001) but not in gastrointestinal tract cancers (HR=1.09, 95% CI: 0.66–1.81, P=0.727). When stratified by tumor type, S100P overexpression predicted poor OS in cholangiocarcinoma (HR=2.14, 95% CI: 1.30–3.50, P=0.003) and hepatocellular carcinoma (HR=1.91, 95% CI: 1.22–2.99, P =0.005) but not in gastric cancer (HR=0.97, 95% CI: 0.65–1.45, P=0.872), colorectal cancer (HR=1.18, 95% CI: 0.32–4.41, P=0.807), gallbladder cancer (HR=1.40, 95% CI: 0.84-2.34, P=0.198), and pancreatic cancer (HR=1.92, 95% CI: 0.99–3.72, P=0.053). Furthermore, high S100P expression was significantly associated with distant metastasis (OR=3.58, P=0.044), advanced clinical stage (OR=2.03, P=0.041) and recurrence (OR=1.66, P=0.007).ConclusionS100P might act as a prognostic indicator of non-gastrointestinal tract cancers.

Download Full-text